{"entity":{"id":"nct06597565","kind":"trial","name":"A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC","aka":[],"tldr":"A phase 2 trial of Prexasertib run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.","summary":"A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC is a phase 2 interventional study registered as NCT06597565 by H. Lee Moffitt Cancer Center and Research Institute, with 43 participants planned, started 2024-09-25. Conditions recorded: Head and Neck Squamous Cell Carcinoma. Interventions recorded: Gemcitabine and ACR-368.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06597565","url":"https://clinicaltrials.gov/study/NCT06597565"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["prexasertib"],"companies":["acrivon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06597565","phase":"2","setting":"A Phase II Study of ACR-368 and Low Dose Gemcitabine Combination Therapy in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06597565/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"prexasertib","kind":"drug","name":"Prexasertib","route":"/drugs/prexasertib/"}],"company":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/"}]}}